ClinicalTrials.gg
RecruitingNCT05361837Updated Jun 30, 2026

Efficacy of Serratus Anterior Plane Block With Dexmedetomidine During Breast Surgery

An interventional study of Single level serratus anterior plane block and Single level serratus anterior plane block with dexmedetomidine in Analgesia, sponsored by National Cancer Institute, Egypt. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by National Cancer Institute, Egypt · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This study aims to compare single level serratus block versus bilevel serratus block with and without dexmedetomidine in cancer patients undergoing modified radical mastectomy for breast cancer regarding pain control and possible side effects.

02

Conditions studied

  • Analgesia
03

In context

Lead sponsor

National Cancer Institute, Egypt is the lead sponsor of 133 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients scheduled for modified radical mastectomy,
  • Age 18-65 years,

Exclusion criteria

Exclusion Criteria:

  • patient refusal,
  • coagulation defects,
  • abnormal kidney or liver functions,
  • local infection at site of injection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
172 participants (estimated)

Study arms

  • Active comparator
    Single level serratus anterior plane block

    the allocated patients will receive single injection serratus anterior plane block at the level of third rib with local anesthetics only

    Procedure: Single level serratus anterior plane block

  • Experimental
    Single level serratus anterior plane block with dexmedetomidine

    the allocated patients will receive single injection serratus anterior plane block at the level of third rib with local anesthetics and dexmedetomidine

    Procedure: Single level serratus anterior plane block with dexmedetomidine

  • Experimental
    Bilevel serratus anterior plane block

    the allocated patients will receive injection serratus anterior plane block at 2 levels, the level of third rib and the level of the fifth rib with local anesthetics only

    Procedure: Bilevel serratus anterior plane block

  • Experimental
    Bilevel serratus anterior plane block with dexmedetomidine

    the allocated patients will receive injection serratus anterior plane block at 2 levels, the level of third rib and the level of the fifth rib with local anesthetics and dexmedetomidine

    Procedure: Bilevel serratus anterior plane block with dexmedetomidine

Interventions

  • ProcedureSingle level serratus anterior plane block

    Serratus anterior plane block with local anesthetics at the third rib

  • ProcedureSingle level serratus anterior plane block with dexmedetomidine

    Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib

  • ProcedureBilevel serratus anterior plane block

    Serratus anterior plane block with local anesthetics at the third and fifth rib

  • ProcedureBilevel serratus anterior plane block with dexmedetomidine

    Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib

06

What researchers measure

Primary outcomes

  1. First time to receive analgesia

    first time to receive morphine analgesia in hours

    Time frame: First 24 hours postoperatively

  2. Total analgesic requisite

    total amount of morphine consumption in the first 24 hours postoperatively in mg

    Time frame: First 24 hours postoperatively

Secondary outcomes

  1. Pain scores

    pain scores will be assessed using Visual Analogue Scale on a sale from 0 to 10 with 0 meanung no pain and 10 meaning severe pain

    Time frame: First 24 hours postoperatively

  2. Side effects

    nausea and vomiting and hematoma at site of injection

    Time frame: First 24 hours postoperatively

  3. Perioperative heart rate values

    heart rate values in the form of beat per minute in the perioperative period including preoperative, intraoperative and postoperative

    Time frame: First 24 hours

  4. Mean arterial blood pressure

    Mean arterial blood pressure values in the form mmHg in the perioperative period including preoperative, intraoperative and postoperative

    Time frame: First 24 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05361837
Responsible party
Walaa Youssef Elsabeeny (Assistant professor of Anesthesia and Pain management, National Cancer Institute, Egypt) — Principal investigator
First posted
May 5, 2022
Start date
May 10, 2022
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 25, 2026 (estimated)
Last update
Jun 30, 2026

Study contacts

Walaa Y Elsabeeny, MD
Contact
walaa.elsabeeny@nci.cu.edu.eg
201007798466 ext. +2
Nahla N Shehab, MD
Contact
nahla.shehab2@gmail.com
01221682808 ext. +2
Walaa Y Elsabeeny, MD
principal investigator · Assistant Professor of Anesthesia and Pain management

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion